A review of the latest leadership moves in the pharma industry.
The companies announced Friday that their candidate survodutide, which is licensed to Boehringer Ingelheim from Zealand Pharma, improved fibrosis in more than 50% of treated patients with metabolic dysfunction-associated steatohepatitis.
Shares of Geron rose more than 16% on Friday before markets opened, a day after the biopharmaceutical company got its first approval from the U.S. Food and Drug Administration for its blood disorder drug Rytelo.
AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
With heavy reliance on Chinese contract manufacturers, U.S. companies are reevaluating their partnerships amidst the proposed regulations aimed at safeguarding national security interests. While the BIOSECURE Act remains a topic of debate, some anticipate potential onshoring benefits, while others foresee disruptions to the existing supply chains, according to GlobalData.
The drug is a potential rival to Eisai and Biogen’s Leqembi, which won approval last July.